☆ 4.0 Review

Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs

ARTHRITIS AND RHEUMATISM (2010)

Get Full Text
Add to Collection

Journal

ARTHRITIS AND RHEUMATISM
Volume 62, Issue 11, Pages 3131-3139

Publisher

WILEY
DOI: 10.1002/art.27670

Keywords

-

Categories

Rheumatology

Funding

  1. Bristol-Myers Squibb
  2. Abbott
  3. Novartis
  4. Roche
  5. Centocor
  6. ACRAF
  7. Pfizer
  8. Xoma
  9. Amgen
  10. UCB
  11. Genen-tech
  12. Wyeth

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.